OGEN - Oragenics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.4542
-0.0119 (-2.55%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.4661
Open0.4700
Bid0.4542 x 2900
Ask0.5140 x 1000
Day's Range0.4500 - 0.4700
52 Week Range0.3500 - 1.0600
Volume478,174
Avg. Volume601,785
Market Cap20.95M
Beta (5Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-0.3870
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
  • We're Keeping An Eye On Oragenics's (NYSEMKT:OGEN) Cash Burn Rate
    Simply Wall St.

    We're Keeping An Eye On Oragenics's (NYSEMKT:OGEN) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • Business Wire

    Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc. will be a featured presenter at the LD Micro Main Event on Tuesday, December 10, 2019 at 1:00 PM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. For those interested in attending or for registered attendees who wish to request meetings, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information. We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.

  • OGEN: AG013 Phase 2 Trial Enrollment Complete…
    Zacks Small Cap Research

    OGEN: AG013 Phase 2 Trial Enrollment Complete…

    By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactis strain that

  • Business Wire

    Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, an easy to use oral rinsing system designed to prevent and treat OM. The ongoing Phase 2 trial is a double-blind, placebo-controlled, two-arm, multi-country, multi-center trial, in which 200 patients have been randomized in a 1:1 ratio to receive either AG013 (“dapatifagene navolactibac”) or a placebo. The purpose of the study (NCT03234465) is to evaluate the safety, tolerability and efficacy of topically administered AG013 compared to placebo for reducing the incidence and severity of OM in patients undergoing traditional chemoradiation (CRT) for the treatment of head and neck cancer (HNC).

  • Business Wire

    Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of the outcome of the a specific chemical synthesis of the bicyclic C/D ring of an analog of the company’s lantibiotic compound, Mutacin 1140. The study, titled “Complete synthesis of the bicyclic ring of a mutacin analog with orthogonally protected lanthionine via solid-phase intracyclization” was published in the recent issue (volume 25, Issue 11) of Journal of Peptide Science.

  • Business Wire

    Oragenics, Inc. SVP of Discovery Research, Martin Handfield, Ph.D. to Be Featured Speaker at the International Conference on Microbial Research and Applications

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the company’s Senior Vice President of Discovery Research, Martin Handfield, MS, Ph.D., will be a featured speaker at the inaugural International Conference on Microbial Research and Applications (MicroBiome 2019). Dr. Handfield will be speaking on November 13, 2019 at 12:20PM ET. The International Conference on Microbial Research and Applications will be held November 13-14, 2019 at the Radisson Hotel, Downton-Inner Harbor in Baltimore, Md. Dr. Handfield’s talk will be titled, “Lantibiotics: a large untapped pipeline of attractive scaffolds for the development of novel antibiotics.” Those interested in attending the talk may register for the conference via its website, https://unitedscientificgroup.com/conferences/microbiology-research/.

  • Business Wire

    Oragenics, Inc. to Present at the BIO Investor Forum

    Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will be presenting at the BIO Investor Forum in San Francisco. The company will present to investors on October 23, 2019, at 2:30 PM ET in the Yorkshire Room of Westin St. Francis in San Francisco. The BIO Investor Forum will be held October 22-23, 2019.

  • OGEN: Phase 2 Trial of AG013 More Than 2/3rd Enrolled…
    Zacks Small Cap Research

    OGEN: Phase 2 Trial of AG013 More Than 2/3rd Enrolled…

    By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Poster on Phase 2 Trial of AG013 Presented at ESMO 2019 On September 30, 2019, Oragenics, Inc. (NYSE:OGEN) announced the presentation of a poster discussing the ongoing Phase 2 clinical trial of AG013 in severe oral mucositis (SOM) at the European Society for Medical Oncology (ESMO) Congress 2019. The company also

  • Business Wire

    Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019

    Oragenics, Inc. (NYSE American:OGEN) (“Oragenics”), a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, today announces initial data from its ongoing Phase 2, placebo-controlled, clinical trial of AG013 in oral mucositis presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain. AG013) in patients being treated with concomitant chemoradiation (CRT) for oral and oropharyngeal cancers (OCOPC),” was presented at the ESMO Congress 2019 in Barcelona, Spain.

  • Who Has Been Buying Oragenics, Inc. (NYSEMKT:OGEN) Shares?
    Simply Wall St.

    Who Has Been Buying Oragenics, Inc. (NYSEMKT:OGEN) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • Oragenics, Inc. (NYSEMKT:OGEN): What Does Its Beta Value Mean For Your Portfolio?
    Simply Wall St.

    Oragenics, Inc. (NYSEMKT:OGEN): What Does Its Beta Value Mean For Your Portfolio?

    Anyone researching Oragenics, Inc. (NYSEMKT:OGEN) might want to consider the historical volatility of the share price...

  • Business Wire

    Oragenics, Inc. to Present Data on Its Peptide Synthesis Platform at the American Peptide Symposium

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces it will be presenting at the American Peptide Symposium on their novel peptide synthesis platform for its lantibiotic pipeline. The presentation is scheduled on Wednesday, June 26, 2019, at the American Peptide Symposium in the Sierra Ballroom of the Monterey Conference Center in Monterey, Calif. Presented by Dr. Jae H. Park, this work demonstrates the peptide synthesis platform developed using orthogonally-protected lanthionine building blocks.

  • Business Wire

    Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of a collaborative study investigating an additional mechanism of action of the company’s lantibiotic compounds, which shows the formation of water permeating pores across bacterial cell membranes. This novel mechanism of action is believed to cause disruption of the bacterial membranes and contribute to our compounds’ antimicrobial mechanism of action.

  • Zacks Small Cap Research

    OGEN: New Pre-Clinical Data Shows Lantibiotic OG253 Safe and Well Tolerated…

    On May 20, 2019, Oragenics, Inc. (OGEN) announced that the 80th patient has been enrolled in the company’s ongoing Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). In addition, the World Health Organization provided the company with the generic name dapatifagene navolactibac for AG013. The trefoil factor family (TFF) is a family of three different peptides secreted by epithelial cells of the gastrointestinal tract in response to injury (Hoffman, 2004).

  • Business Wire

    Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis

    “We continue to increase the number of clinical sites across the globe with 48 of the 61 identified clinical sites actively enrolling patients for our Phase 2 clinical trial of AG013,” stated Alan Joslyn, Ph.D., President and Chief Executive Officer of Oragenics, Inc. “In the meantime, we are pleased to have an agreed upon generic designation for AG013, which will now also be referred to as dapatifagene navolactibac, to allow us a more specific way of referring to the compound moving forward.

  • Business Wire

    Newly Published Preclinical Data on Oragenics, Inc.’s Lantibiotic Compound Demonstrates Tolerability and Compartmentalization to the GI Tract

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the publication of preclinical data of the company’s lantibiotic compound OG253, a predecessor to its current lead lantibiotics compound OG716, when administered in animal models in the July 2019 peer review journal, Toxicology and Applied Pharmacology (https://doi.org/10.1016/j.taap.2019.04.019).

  • Introducing Oragenics (NYSEMKT:OGEN), The Stock That Collapsed 98%
    Simply Wall St.

    Introducing Oragenics (NYSEMKT:OGEN), The Stock That Collapsed 98%

    Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for those who held Oragenics, Inc. (NYSEMKT:OG...

  • Zacks Small Cap Research

    OGEN: 60th Patient Enrolled into Phase 2 Trial of AG013; Data in 1H2020…

    On March 15, 2019, Oragenics, Inc. (OGEN) announced that the 60th patient has been enrolled in the company’s ongoing Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactis strain that contains the coding sequence for human trefoil family factor 1 (hTFF1), which is continually secreted by the bacteria. The Phase 2 trial (NCT03234465) is expected to enroll approximately 160-180 subjects with head and neck cancer receiving chemotherapy and radiation who will receive either AG013 (2.0 x 1011 CFU) or placebo administered three times a day over 7-9 weeks (depending on the subject’s treatment plan).

  • Business Wire

    Oragenics, Inc. to Present at Spring Investor Summit on April 1, 2019

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will present and meet with investors at Spring Investor Summit on April 1, 2019 at 1:00 PM ET as part of Track 1 at The Essex House in New York City. We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries.

  • Business Wire

    Oragenics, Inc. Enters into Collaboration with Florida International University to Expand Its Pipeline of Lantibiotics

    Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the initiation of a collaboration with Florida International University (FIU) to create computational models of the company’s lantibiotic compounds interacting with bacterial membranes and Lipid II, the target of Oragenics’ compounds with the ultimate goal of expanding the lantibiotic pipeline.

  • Business Wire

    Oragenics Announces Closing of $12.5 Million Underwritten Public Offering

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced the closing of its previously announced underwritten public offering of 16,666,668 shares of common stock, short-term warrants to purchase up to 8,333,334 shares of common stock, and long-term warrants to purchase up to 8,333,334 shares of common stock, at a price to the public of $0.75 per share and accompanying warrants. Oragenics expects to receive gross proceeds of approximately $12.5 million from the offering. H.C. Wainwright & Co. is acting as sole book-running manager for the offering.